Cytokine production and the pathogenesis of experimental autoimmune neuritis and Gulllain-Barre syndrome

Journal of Neuroimmunology

Volumn 84, Issue 1, 1998, Pages 40-52

  Zhu, Jie ^a   Mix, Eilhard ^b   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Autoimmunity; Cytokine; Experimental allergic neuritis; Guillain Barre syndrome; T cell

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DEMYELINATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; POLYRADICULONEUROPATHY;

EID: 0032054104     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00238-5     Document Type: Article

References (106)

1. Abromson-Leeman S., Bronson R., Dorf M.E. Experimental autoimmune peripheral neuritis induced in BALB/c mice by myelin basic protein-specific T cell clones. J. Exp. Med. 182:1995;587-592.
2. Adorini L., Sinigaglia F. Pathogenesis and immunotherapy of autoimmune diseases. Immunol. Today. 18:1997;209-211.
3. Armati P.J., Pollard J.D. Immunology of the Schwann cell. Bailliere's Clin. Neurol. 5:1996;47-64.
4. Bai X.F., Zhu J., Zhang G.X., Kaponides G., Höjeberg B., van der Meide P.H., Link H. IL-10 suppresses experimental allergic neuritis, and down-regulates cytokine mRNA expression of Th1 and macrophage source. Clin. Immunol. Immunopathol. 2:1997;117-126.
5. Bai X.F., Shi F.D., Zhu J., Xiao B.G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
6. Bansil S., Mithen F.A., Cook S.D., Sheffet A., Rohowsky K.C. Clinical correlation with serum-soluble interleukin-2 receptor levels in Guillain-Barré syndrome. Neurology. 41:1991;1302-1305.
7. Bengtsson B.O., Zhu J., Thorell L.H., Olsson T., Link H., Walinder J. Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats. J. Neuroimmunol. 39:1992;109-122.
8. Blanas E., Carbone F.R., Allison J., Miller J.F.A.P., Heath W.R. Induction of autoimmune diabetes by oral administration of autoantigen. Science. 274:1996;1707-1709.
9. Bolin L.M., Verity A.N., Silver J.E., Shooter E.M., Abrams J.S. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J. Neurochem. 64:1995;850-858.
10. Cavender D.E., Edelbaum D., Ziff M. Endothelial cell activation induced by tumor necrosis factor and lymphotoxin. Am. J. Pathol. 134:1989;551-560.
11. Chelmicka-Schorr E., Kwasniewski M.N., Thomasn B.E., Arnason B.G.W. The β-adrenergic agonist isoproterenol suppresses EAE in Lewis rats. J. Neuroimmunol. 25:1989;203-207.
12. Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller-Fisher syndrome. Brain Res. 16:1997;32-36.
13. Constantinescu C.S., Hilliard B., Lavi E., Ventura E., Venkatesh V., Rostami A. Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoylfylline. J. Neurol. Sci. 143:1996;14-18.
14. Crawford R.M., Finbloom D.S., Ohara J., Paul W.E., Meltzer M.S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J. Immunol. 139:1987;135-141.
15. Creange A., Belec L., Clair B., Raphael J.C., Gherardi R.K. Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome. J. Neuroimmunol. 68:1996;95-99.
16. de Waal-Malefyt R., Abrams J., Beneett B., Figdor C.G., de Vries J.E. IL-10 inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1991;1209-1220.
17. Dahle C., Ekerfelt C., Vrethem M., Samuelsson M., Ernerudh J. Th2-like responses to P0 and P2 peptides in the recovery phase of the Guillain-Barré syndrome. Acta Neurol. Scand. 94(suppl. 167):1996;99. (abstract).
18. Duong T.T., Finkelman F.D., Singh B., Strejan G.H. Effect of anti-interferon-γ monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J. Neuroimmunol. 53:1994;101-107.
19. Enders U., Toyka K.V., Hartung H.-P., Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J. Neuroimmunol. 76:1997;112-116.
20. Exley A.R., Smith N., Winer J.B. Tumour necrosis factor-α and other cytokines in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 57:1994;1118-1120.
21. Fomsgaard A., Svenson M., Bendtzen K. Auto-antibodies to tumour necrosis factor-α in healthy human and patients with inflammatory diseases and gram-negative bacterial infections. Scand. J. Immunol. 30:1989;219-223.
22. H2 clones. J. Immunol. 144:1990;4110-4120.
23. Gasser D.L., Newlin C.M., Palm J., Gonatas N.K. Genetic control of susceptibility to experimental autoimmune encephalomyelitis in rats. Science. 181:1973;872-873.
24. Genain C.P., Abel K., Belmas N., Villinger F., Rosenberg D.P., Linington C., Raine C.S., Hauser S.L. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
25. Giovannoni G., Hartung H.P. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr. Opin. Neurol. 9:1996;165-177.
26. Gold R., Toyka K.V., Hartung H.P. Synergistic effect of IFN-γ and TNF-α on expression of immune molecules and antigen presentation by Schwann cell. Cell Immunol. 165:1995;65-70.
27. Gold R., Zielasek J., Kiefer R., Toyka K.V., Hartung H.P. Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. Cell Immunol. 168:1996;69-77.
28. Gregorian S.K., Lee W.P., Beck L.S., Rostami A., Amento E.P. Regulation of experimental autoimmune neuritis by transforming growth factor-β1. Cell Immunol. 156:1994;102-112.
29. Griffin, H.W., Ho, T., Wesselingh, S.L., Li, C.Y., Asbury, A.K., 1993. Immunopathology of the Guillain-Barré syndrome. Peripheral Nerve Study Group 11th Biennial Meeting (abstract). Institute of Neuropathology, Jakobsberg, Boppard, Aachen, Germany, pp. 7, 95.
30. Guénard V., Rosenbaum T., Gwynn L.A., Doetschman T., Ratner N., Wood P.M. Effect of transforming growth factor-β1 and -β2 on Schwann cell proliferation on neurites. Glia. 13:1995;309-318.
31. Hamaguchi K., Ohno R., Tsuji T., Yamashita T., Negishi T., Nomura K., Hosokawa T. Activated T lymphocyte subsets in experimental allergic neuritis. J. Neuroimmunol. 34:1991;191-196.
32. Hartung H.P., Toyka K.V. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann. Neurol. 27:1990;S57-S63. (suppl).
33. Hartung H.P., Schäfer B., Fierz W., Heininger K., Toyka K.V. Cyclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neurosci. Lett. 83:1987;195-200.
34. Hartung H.P., Schäfer B., Diamantstein T., Fierz W., Heininger K., Toyka K.V. Suppression of P2-T cell line-mediated experimental autoimmune neuritis by interleukin-2 receptor targeted monoclonal antibody ART 18. Brain Res. 489:1989;120-128.
35. Hartung H.P., Schäfer B., van der Meide P.H., Fierz W., Heininger K., Toyka K.V. The role of interferon-γ in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann. Neurol. 27:1990;247-257.
36. Hartung H.P., Reiners K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis. Ann. Neurol. 30:1991;48-53.
37. Hartung, H.-P., Stoll, G., Toyka, K.V., 1993. Immune reactions in the peripheral nervous system. In: Dyck, D.J., Thomas, P.K., Griffín, J.W., Low, P.A., Poduslo, J.F. (Eds.), Peripheral Neuropathy. Saunders, Philadelphia, PA, pp. 418-444.
38. Hartung H.P., Pollard J.D., Harvey G., Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré syndrome: Part I. Muscle Nerve. 18:1995;137-153.
39. Hartung H.P., Willison H., Jung S., Pette M., Toyka K.V., Giegerich G. Autoimmune response in peripheral nerve. Springer Semin. Immunopathol. 18:1996;97-123.
40. Hirayama M., Kiyosawa K., Nakazaki S., Fujiki N., Iida M. Measurement of γ-interferon in sera and CSF in patients with multiple sclerosis and inflammatory neurological diseases. Clin. Neurol. 30:1990;557-559.
41. Hodgkinson S.J., Westland K.W., Pollard J.D. Transfer of experimental allergic neuritis by intraneural injection of sensitized lymphocytes. J. Neurol. Sci. 123:1994;162-172.
42. Jander S., Pohl J., Gillen C., Stoll G. Differential expression of interleukin-10 mRNA in Wallerian degeneration and immune-mediated inflammation of the rat peripheral nervous system. J. Neurosci. Res. 43:1996;254-259.
43. Jung S., Schluesener H.J., Schmidt B., Fontana A., Toyka K.V., Hartung H.P. Therapeutic effect of transforming growth factor-β2 on actively induced EAN but not adoptive transfer EAN. Immunology. 83:1994;545-551.
44. Kadlubowski M., Hughes R.A.C. Identification of the neurotogen for experimental allergic neuritis. Nature. 277:1979;140-141.
45. Kelso A. Th1 and Th2 subsets: Paradigms lost? Immunol. Today. 16:1995;374-379.
46. Khalili-Shirazi A., Hughes R.A.C., Brostoff S.W., Linington C., Gregson N. T cell responses to myelin in Guillain-Barré syndrome. J. Neurol. Sci. 111:1992;200-203.
47. Kiefer R., Gold R., Gehrmann J., Lindholm D., Wekerle H., Kreutzberg G.W. Transforming growth factor-β expression in reactive spinal cord microglia and meningeal inflammatory cells during experimental allergic neuritis. J. Neurosci. Res. 36:1993;391-398.
48. Kiefer R., Funa K., Schweitzer T., Jung S., Bourde O., Toyka K.V., Hartung H.P. Transforming growth factor-β1 in experimental allergic neuritis. Cellular localization and time course. Am. J. Pathol. 148:1996;211-223.
49. Klinkert W.E., Kojima K., Lesslauer W., Rinner W., Lassmann H., Wekerle H. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: An overview. J. Neuroimmunol. 72:1997;163-168.
50. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., Shah K., Mulvany K., Hora D., Cunningham P., Wunderler D.L., McManus O.B., Slaughter R., Bugianesi R., Felix J., Garcia M., Williamson J., Kaczorowski G., Sigal N.H., Springer M.S., Feeney W. Blockade of voltage-gated potassium channel Kv1.3 inhibits immune response vivo. J. Immunol. 158:1997;5120-5128.
51. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 80:1995;707-718.
52. Kusunoki S. Antiglycolipid antibody in inflammatory neuropathy. Rinsho Shinkeigaku. 35:1995;1370-1372.
53. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today. 16:1995;34-38.
54. Lin C.S., Boltz R.C., Blake J.T., Nguyen M., Talento A., Fischer P.A., Springer M.S., Sigal N.H., Slaughter R.S., Garcia M.L., Kaczorowski G.J., Koo G.C. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177:1993;637-645.
55. Linington C., Izumo S., Suzuki M., Uyemura K., Meyermann R., Wekerle H. A permanent rat cell line that mediates experimental allergic neuritis in the Lewis rats in vivo. J. Immunol. 133:1984;1946-1950.
56. Linington C., Lassmann H., Ozawa K., Kosin S., Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: Induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur. J. Immunol. 22:1992;1813-1817.
57. Link J., He B., Navikas V., Palasik W., Fredrikson S., Söderström M., Link H. TGF-β suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of IL-10 in multiple sclerosis and myasthenia gravis. J. Neuroimmunol. 58:1995;21-35.
58. Maeda Y., Maeda R., Prineas J.W., Ledeen R.W. Phosphatidylserine suppresses myelin-induced experimental allergic neuritis (EAN) in Lewis rats. J. Neuropathol. Exp. Neurol. 53:1994;672-677.
59. Maimone D., Annuniziata P., Simone I.L., Livrea P., Guazzi G.C. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 47:1993;55-61.
60. McFarland H.F. Complexities in the treatment of autoimmune disease. Science. 274:1996;2037-2038.
61. Milner P.A., Lovelidge C.A., Taylor W.A., Hughes R.A.C. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J. Neurol. Sci. 79:1987;275-285.
62. Mix E., Olsson T., Solders G., Link H. Effect of ion channel blockers on immune response and course of experimental allergic neuritis. Brain. 112:1989;1405-1418.
63. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
64. Murwani R., Hodgkinson S., Armati P. Tumor necrosis factor alpha and IL-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon-γ J. Neuroimmunol. 71:1996;65-71.
65. Nagler-Anderson C., Lichtenheld M., Eisen H.N., Podack E.R. Perforin mRNA in primary peritoneal exudate cytotoxic T lymphocytes. J. Immunol. 143:1989;3440-3443.
66. O'Garra A., Murphy K. Role of cytokines in development of Th1 and Th2 cells. Chem. Immunol. 63:1996;1-13.
67. Olee T., Powell H.C., Brostoff S.W. New minimum length requirement for a T cell epitope for experimental allergic neuritis. J. Neuroimmunol. 27:1990;187-190.
68. Pernis A., Gupta S., Gollob K.J., Garfein E., Coffman R.L., Schindler C., Rothman P. Lack of interferon-γ receptor beta chain and the prevention of interferon-γ signaling in TH1 cells. Science. 269:1995;245-247.
69. Ponzin D., Menegus A.M., Kirschner G., Nunzi M.G., Fiori M.G., Raine C.S. Effects of gangliosides upon the expression of autoimmune demyelination in the peripheral nervous system. Ann. Neurol. 30:1991;678-685.
70. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α Proc. Natl. Acad. Sci. U.S.A. 92:1995;11294-11298.
71. Racke M.K., Sriram S., Carlino J., Cannella B., Raine C.S., McFarlin D.E. Long-term treatment of chronic-relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J. Neuroimmunol. 46:1993;175-184.
72. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain. 118:1995;869-878.
73. Romagnani S. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol. 4:1996;470-473.
74. Rostami A.M. Guillain-Barré syndrome: Clinical and immunological aspects. Springer Semin. Immunopathol. 17:1995;29-42.
75. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1994;1434-1440.
76. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.I., Padula S.I., Clark R.B. An antibody to lymphotoxin an tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
77. Ruegemer J.J., Ho S.N., Augustine J.A., Schlager J.W., Bell M.P., Mckean D.J., Abraham R.T. Regulatory effects of transforming growth factor β on IL-2- and IL-4-dependent T cell-cycle progression. J. Immunol. 144:1990;1767-1776.
78. Said G., Hontebeyrie-Joskowiecz M. Nerve lesions induced by macrophage activation. Res. Immunol. 143:1992;589-599.
79. Schmidt B., Stoll G., van der Meide P., Jung S., Hartung H.P. Transient cellular expression of γ-interferon in myelin-induced and T-cell line-mediated experimental autoimmune neuritis. Brain. 115:1992;1633-1646.
80. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
81. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor. J. Neuroimmunol. 56:1995;135-141.
82. Sharief M.K., Mclean B., Thompson E.J. Elevated serum levels of tumor necrosis factor-α in Guillain-Barré syndrome. Ann. Neurol. 33:1993;591-596.
83. Shull M.M., Ormsby I., Kier A., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunzziata N., Doetschmann T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
84. Sindern E., Schweppe K., Ossege L.M., Malin J.P. Potential role of transforming growth factor-beta-1 in terminating the immune response in patients with Guillain-Barré syndrome. J. Neurol. 243:1996;264-268.
85. Sivieri S., Ferrarini A.M., Lolli F., Mata S., Pinto F., Tavolato B., Gallo P. Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J. Neurol. Sci. 147:1997;93-95.
86. Spies J.M., Wesaland K.W., Bonner J.G., Pollard J.D. Intraneural activated T-cells cause focal breakdown of the blood-nerve barrier. Brain. 118:1995;857-868.
87. Stoll G., Jung S., Jander S., van der Meide P., Hartung H.P. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J. Neuroimmunol. 45:1993;175-182.
88. Strigård K., Holmdahl R., van der Meide P.H., Klarekog L., Olsson T. In vivo treatment of rats with monoclonal antibodies against gamma interferon: Effects on experimental allergic neuritis. Acta Neurol. Scand. 80:1989;201-207.
89. Thompson C.B. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 81:1995;979-982.
90. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol. Today. 14:1995;335-338.
91. Tsai C.P., Pollard J.D., Armati P.J. Interferon-γ inhibition suppresses experimental allergic neuritis: Modulation of major histocompatibility complex expression on Schwann cells in vitro. J. Neuroimmunol. 31:1991;133-145.
92. Van der Veen R.C., Kapp J.A., Trotter J.L. Fine-specificity differences in the recognition of an encephalitogenic peptide by T helper 1 and 2 cells. J. Neuroimmunol. 48:1993;221-226.
93. Vrethem M., Skogh T., Berlin G., Holmgren H., Ernerudh J. Antibodies to peripheral nerve myelin may occur without clinical neuropathy in healthy persons. J. Neuroimmunol. 32:1991;219-222.
94. Vriesendrop F.J., Flynn R.E., Khan M., Pappolla M.A., Brod S.A. Oral administration of type-I interferon modulates the course of experimental allergic neuritis. Autoimmunity. 24:1996;157-165.
95. Weber F., Meinl E., Aloisi F., Nevinny-Stickel C., Albert E., Wekerle H., Hohlfeld R. Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis. Brain. 117:1994;59-69.
96. Weller M., Stevens A., Sommer N., Melms A., Dichgans J., Wietholter H. Comparative analysis of cytokine patterns in immunological infectious, and oncological neurological disorders. J. Neurol. Sci. 104:1991;215-221.
97. Wu Z., Podack E.R., Mckenzie J.M., Olsen K.J., Zakarija M. Perforin expression by thyroid-infiltrating T cells in autoimmune thyroid disease. Clin. Exp. Immunol. 98:1994;470-477.
98. Zhang G.X., Navikas V., Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve. 20:1997;543-551.
99. Zhu J., Link H., Mix E., Olsson T., Huang W.-X. Th1-like cell responses to peripheral nerve myelin components over the course of experimental allergic neuritis in Lewis rats. Acta Neurol. Scand. 90:1994;19-25.
100. Zhu J., Link H., Weerth S., Linington C., Mix E., Qiao J. The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J. Neurol. Sci. 125:1994;132-137.
101. Zhu J., Mix E., Olsson T., Link H. Cellular mRNA expression of interferon-γ, interleukin 4 and transforming growth factor-β by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin. Exp. Immunol. 98:1994;306-312.
102. Zhu J., Mix E., Issazadeh S., Link H. Dynamics of mRNA expression of interferon-γ, interleukin-4 and transforming growth factor-β in sciatic nerves and lymphoid organs in experimental allergic neuritis. Eur. J. Neurol. 3:1996;232-240.
103. Zhu J., Bai X.F., Mix E., Höjeberg B., Link H. Cytokines dichotomy in the peripheral nervous tissues influence the outcome of experimental allergic neuritis: Dynamics of mRNA expression for IL-1β, IL-6, IL-10, IL-12, tumor necrosis factor-α and TFN-β as well as cytolysin. Clin. Immunol. Immunopathol. 84:1997;85-94.
104. Zhu, J., Bai, X.F., Mix, E., Link, H., 1997b. Experimental allergic neuritis: Cytolysin mRNA expression is upregulated in lymph node cells during convalescence. J. Neuroimmunol. (in press).
105. Zielasek J., Ritter G., Magi S., Hartung H.P., Toyka K.V. A comparative trial of anti-glycoconjugate antibody assay: IgM antibodies to GM1. J. Neurol. 241:1994;475-480.
106. Zielasek J., Jung S., Gold R., Liew F.Y., Toyka K.V., Hartung H.P. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58:1995;81-88.